NCT03220009 2018-10-03Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaNational Cancer Institute (NCI)Phase 2 Withdrawn
NCT00411281 2015-09-30Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative DisorderChildren's Oncology GroupPhase 3 Withdrawn